Mannan, A Potential Therapeutic for Asthma

甘露聚糖，一种治疗哮喘的潜在药物

• 批准号: 7591462
• 负责人: DUKHEE Betty LEW
• 金额: $ 11.18万
• 依托单位: CUMBERLAND PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7591462
• 关键词: Address; Adverse effects; Airway Resistance; Allergic; Asthma; Breathing; Carbohydrates; Cell Culture System; Childhood Asthma; Clinical Trials; Disease; Dose; Emerging Technologies; Goals; Human; Hyperplasia; Hypersensitivity; Immunology; Immunomodulators; In Vitro; Inflammation; Inflammatory; Intranasal Administration; Knowledge; Laboratories; Lead; Mannans; Medicine; Modeling; Mus; Oral; Oral Administration; Ovalbumin; Pharmacologic Substance; Phase; Powder dose form; Rhinitis; Route; Saccharomyces; Saccharomyces cerevisiae; Small Business Technology Transfer Research; Smooth Muscle; Smooth Muscle Myocytes; Solutions; Source; System; Tennessee; Testing; Therapeutic; Time; Toxic effect; Transgenic Organisms; Universities; airway hyperresponsiveness; airway inflammation; aqueous; asthmatic patient; base; college; commercial application; in vivo; mannose receptor; methacholine; mouse model; muscle hypertrophy; novel; pediatric department; pre-clinical; prebiotics; preclinical study; prevent; public health relevance; respiratory; respiratory smooth muscle

DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of beneficial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s laboratory have shown that mannan from S. cerevisiae, a carbohydrate-based prebiotic polymannose agent, inhibits airway inflammation, hyperreactivity (AHR) and ASM remodeling. Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. Studies are proposed 1) to determine the optimum dose and dose timing of mannan administered intranasally. 2) to determine the optimum dose and dose timining of mannan administered orally. The University of Tennessee College of Medicine Department of Pediatric Allergy/Immunology and Cumberland Emerging Technologies Inc (CET), an affiliate of Cumberland Pharmaceuticals Inc (CPI), are collaborating to identify and develop promising pharmaceutical therapies for treating and preventing asthma. The P.I. will conduct preclinical studies outlined in the proposal and CET will develop the product for the preclinical and clinical trials. The knowledge gained from these studies will provide a novel class of adjuctive asthma therapy that will modulate ASM remodeling and will lead to a unique intranasal and oral products that will benefit asthmatics and patients with other related diseases. PUBLIC HEALTH RELEVANCE: Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy.

描述（由申请人提供）：本申请的长期目标是开发从贝克酵母中提取的甘露聚糖作为哮喘治疗。目前可用的免疫调节剂的局限性在于其在高剂量下的毒性和对气道平滑肌（ASM）重塑缺乏有益作用，因此需要新的辅助治疗方法。调查的初步发现来自酿酒酵母的甘露糖是一种基于碳水化合物的益生元多甘露糖制剂，可以抑制气道炎症、高反应性（AHR）和ASM重塑。我们的中心假设是来自酿酒酵母的甘露聚糖是一类抑制ASM重塑的新型免疫调节剂。研究建议1)确定甘露聚糖鼻内给药的最佳剂量和给药时间。2)确定甘露聚糖口服给药的最佳剂量和给药时间。田纳西大学医学院儿科过敏/免疫学系和坎伯兰新兴技术公司（CET），坎伯兰制药公司（CPI）的子公司，正在合作确定和开发治疗和预防哮喘的有前途的药物疗法。P.I.将进行提案中概述的临床前研究，而CET将为临床前和临床试验开发产品。从这些研究中获得的知识将提供一种新型的辅助性哮喘治疗，它将调节ASM重塑，并将导致一种独特的鼻内和口服产品，这将使哮喘患者和其他相关疾病患者受益。公共卫生相关性：我们的中心假设是酿酒葡萄球菌的甘露聚糖是一类抑制ASM重塑的新型免疫调节剂。这项应用的长期目标是开发从贝克酵母中提取的甘露聚糖作为哮喘治疗。

项目成果

Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models.

• DOI: 10.1155/2017/3432701
• 发表时间: 2017
• 期刊: Journal of immunology research
• 影响因子: 4.1
• 作者: Lew DB;Michael CF;Overbeck T;Robinson WS;Rohman EL;Lehman JM;Patel JK;Eiseman B;LeMessurier KS;Samarasinghe AE;Gaber MW
• 通讯作者: Gaber MW